Skip to main content
Erschienen in: Digestive Diseases and Sciences 6/2013

01.06.2013 | Original Article

Risk of Complications After a Peptic Ulcer Diagnosis: Effectiveness of Proton Pump Inhibitors

verfasst von: Sonia Hernández-Díaz, Elisa Martín-Merino, Luis A. García Rodríguez

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Few studies have evaluated the prevention of upper gastrointestinal complications (UGIC; bleeding or perforation) in patients with uncomplicated peptic ulcer (PU). We assessed the effect of proton pump inhibitors (PPI) in a non-randomized setting. To maximize exchangeability of exposed and unexposed groups we restricted the study to patients with a new diagnosis of PU, i.e., a clear indication. To minimize selection bias we mimicked an intention to treat approach by assessing the effect of PPI prescription after PU diagnosis.

Methods

Within a population of subjects aged 40–84 years from The Health Improvement Network database, 1997–2006, we identified 3,850 patients with incident PU. Among them, we confirmed 74 first UGIC episodes during a mean follow-up of 4 years. Exposure was prescription coverage during the month following PU diagnosis. We performed a nested case–control analysis and compared UGIC cases with 400 controls matched for age, sex, year and duration of follow-up. Relative risks (RR) and 95 % confidence intervals (CI) were estimated.

Results

The overall incidence of UGIC was 4.6 cases/1,000 person-years; it was highest during the months after PU diagnosis, increased with age, and it was higher in men and subjects with Helicobacter pylori infection, anemia, and alcohol use at PU diagnosis. The RR for UGIC associated with PPI prescriptions during the month after PU diagnosis was 0.56 (95 % CI 0.31–1.0). The RR for NSAIDs with and without a PPI was 1.72 (0.68–4.45) and 3.27 (0.85–12.67), respectively.

Conclusions

Findings suggest that prescription of PPIs after a PU diagnosis is associated with a reduced risk of UGIC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hernández-Díaz S, García Rodríguez L. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol. 2002;55:157–163.PubMedCrossRef Hernández-Díaz S, García Rodríguez L. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol. 2002;55:157–163.PubMedCrossRef
2.
Zurück zum Zitat García Rodríguez L, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998;158:33–39.PubMedCrossRef García Rodríguez L, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998;158:33–39.PubMedCrossRef
3.
Zurück zum Zitat Hernández-Díaz S, García-Rodríguez L. Overview of epidemiological studies published in the nineties on the association between non-steroidal anti-inflammatory drugs and upper gastrointestinal bleed/perforation. Arch Intern Med. 2000;160:2093–2099.PubMedCrossRef Hernández-Díaz S, García-Rodríguez L. Overview of epidemiological studies published in the nineties on the association between non-steroidal anti-inflammatory drugs and upper gastrointestinal bleed/perforation. Arch Intern Med. 2000;160:2093–2099.PubMedCrossRef
4.
Zurück zum Zitat Hawkey C, Jeffrey A, Szczepnski L, et al. A comparison of omeprazole and misoprostol for treating and preventing ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med. 1998;338:727–734.PubMedCrossRef Hawkey C, Jeffrey A, Szczepnski L, et al. A comparison of omeprazole and misoprostol for treating and preventing ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med. 1998;338:727–734.PubMedCrossRef
5.
Zurück zum Zitat Yeomans N, Tulassay Z, Juhasz L, et al. A comparison of omeprazole and ranitidine for treating and preventing ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med. 1998;338:719–726.PubMedCrossRef Yeomans N, Tulassay Z, Juhasz L, et al. A comparison of omeprazole and ranitidine for treating and preventing ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med. 1998;338:719–726.PubMedCrossRef
6.
Zurück zum Zitat Silverstein F, Graham D, Senior J, et al. Misoprostol reduces serious gastrointestinal complication in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241–249.PubMedCrossRef Silverstein F, Graham D, Senior J, et al. Misoprostol reduces serious gastrointestinal complication in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241–249.PubMedCrossRef
7.
Zurück zum Zitat García-Rodríguez L, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12:570–576.PubMedCrossRef García-Rodríguez L, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12:570–576.PubMedCrossRef
8.
Zurück zum Zitat Jensen D, Cheng S, Kovacs T, et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med. 1994;330:382–386.PubMedCrossRef Jensen D, Cheng S, Kovacs T, et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med. 1994;330:382–386.PubMedCrossRef
9.
Zurück zum Zitat Lai K, Lam S, Chu K, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033–2038.PubMedCrossRef Lai K, Lam S, Chu K, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033–2038.PubMedCrossRef
10.
Zurück zum Zitat García Rodríguez L, Ruigómez A. Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. Epidemiology. 1999;10:228–232.PubMedCrossRef García Rodríguez L, Ruigómez A. Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. Epidemiology. 1999;10:228–232.PubMedCrossRef
11.
Zurück zum Zitat Walker AM. Observation and inference. An introduction to the methods of epidemiology. Newton Lower Falls: Epidemiology Resources Inc.; 1991. Walker AM. Observation and inference. An introduction to the methods of epidemiology. Newton Lower Falls: Epidemiology Resources Inc.; 1991.
12.
Zurück zum Zitat Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–920.PubMedCrossRef Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–920.PubMedCrossRef
13.
Zurück zum Zitat Hernán M, Brumback B, Robins J. Marginal structural models to estimate the joint effect of non randomized treatments. J Am Stat Assoc. 2001;96:440–448.CrossRef Hernán M, Brumback B, Robins J. Marginal structural models to estimate the joint effect of non randomized treatments. J Am Stat Assoc. 2001;96:440–448.CrossRef
14.
Zurück zum Zitat Hernán M, Robins J. Instrumental variables for causal inference: an epidemiologist dream? Epidemiology. 2006;17:360–372.PubMedCrossRef Hernán M, Robins J. Instrumental variables for causal inference: an epidemiologist dream? Epidemiology. 2006;17:360–372.PubMedCrossRef
15.
Zurück zum Zitat Hernan MA, Hernandez-Diaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9:48–55.PubMedCrossRef Hernan MA, Hernandez-Diaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9:48–55.PubMedCrossRef
16.
Zurück zum Zitat Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12:171–177.PubMed Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12:171–177.PubMed
19.
Zurück zum Zitat Margulis AV, Garcia Rodriguez LA, Hernandez-Diaz S. Positive predictive value of computerized medical records for uncomplicated and complicated upper gastrointestinal ulcer. Pharmacoepidemiol Drug Saf. 2009;18:900–909.PubMedCrossRef Margulis AV, Garcia Rodriguez LA, Hernandez-Diaz S. Positive predictive value of computerized medical records for uncomplicated and complicated upper gastrointestinal ulcer. Pharmacoepidemiol Drug Saf. 2009;18:900–909.PubMedCrossRef
20.
Zurück zum Zitat Andersen IB, Jorgensen T, Bonnevie O, Gronbaek M, Sorensen TI. Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population based cohort study. Epidemiology. 2000;11:434–439.PubMedCrossRef Andersen IB, Jorgensen T, Bonnevie O, Gronbaek M, Sorensen TI. Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population based cohort study. Epidemiology. 2000;11:434–439.PubMedCrossRef
21.
Zurück zum Zitat Lanas A, Remacha B, Esteva F, Sainz R. Risk factors associated with refractory peptic ulcers. Gastroenterology. 1995;109:1124–1133.PubMedCrossRef Lanas A, Remacha B, Esteva F, Sainz R. Risk factors associated with refractory peptic ulcers. Gastroenterology. 1995;109:1124–1133.PubMedCrossRef
22.
Zurück zum Zitat Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;115:787–796.PubMedCrossRef Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;115:787–796.PubMedCrossRef
23.
Zurück zum Zitat Patrono C, Coller B, Dalen J, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2004;126:234S–264S.PubMedCrossRef Patrono C, Coller B, Dalen J, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2004;126:234S–264S.PubMedCrossRef
24.
Zurück zum Zitat Fitzgerald G, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433–442.PubMedCrossRef Fitzgerald G, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433–442.PubMedCrossRef
25.
Zurück zum Zitat Laine L. Review article: the effect of Helicobacter pylori infection on non-steroidal anti-inflammatory drug-induced upper gastrointestinal tract injury. Aliment Pharmacol Ther. 2002;16:34–39.PubMedCrossRef Laine L. Review article: the effect of Helicobacter pylori infection on non-steroidal anti-inflammatory drug-induced upper gastrointestinal tract injury. Aliment Pharmacol Ther. 2002;16:34–39.PubMedCrossRef
26.
Zurück zum Zitat Hopkins R, Girardi L, Turney E. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996;110:1244–1252.PubMedCrossRef Hopkins R, Girardi L, Turney E. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996;110:1244–1252.PubMedCrossRef
Metadaten
Titel
Risk of Complications After a Peptic Ulcer Diagnosis: Effectiveness of Proton Pump Inhibitors
verfasst von
Sonia Hernández-Díaz
Elisa Martín-Merino
Luis A. García Rodríguez
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 6/2013
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2561-9

Weitere Artikel der Ausgabe 6/2013

Digestive Diseases and Sciences 6/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.